Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US  by Aggarwal, Ajay et al.
RC
f
A
a
b
c
a
A
A
K
A
C
P
A
R
C
F
h
2Journal of Cancer Policy 2 (2014) 1–11
Contents lists available at ScienceDirect
Journal  of  Cancer  Policy
jou rn al h om epage: www.elsev ier .com/ locate / j cpo
eview
ancer  economics,  policy  and  politics:  What  informs  the  debate?  Perspectives
rom  the  EU,  Canada  and  US
jay  Aggarwala,∗,1, Ophira  Ginsburgb,1, Tito  Fojoc,1
Institute of Cancer Policy, Kings College London, Guy’s Hospital Campus, Department of Research Oncology, London SE1 9RT, United Kingdom
Women’s College Research Institute, Faculty of Medicine and Dalla Lana School of Public Health, University of Toronto, Canada
Medical Oncology, National Cancer Institute, National Institutes of Health, Building 10, Room 12N226, 9000 Rockville Pike, Bethesda, MD 20892, USA
 r  t  i  c  l  e  i  n  f  o
rticle history:
vailable online 28 February 2014
eywords:
dvocacy
ancer economics
olicy
ccess
egional variations
a  b  s  t  r  a  c  t
In high-income  countries  the  public  policy  consensus  is  that costs  of delivering  high-quality  equitable
cancer  care  present  an  increasing  challenge  to national  budgets.  In the  U.S.  alone  it is estimated  cancer
care  expenditures  in  2020  will  be 157 billion  dollars.  The  increase  is being  driven  by  a  number  of  factors
including  technological  innovation,  rising  costs  of  medical  and  hospital  care,  expensive  therapeutics  and
an  increase  in the  proportion  of  individuals  susceptible  to  malignancy  as the  population  ages.  In this
article  we  review  what  factors are  informing  and  inﬂuencing  the  political  debate  on cancer  economics
across  Europe  and  North  America.
We have  undertaken  a comprehensive  analysis  of  the  literature  and  supplemented  this  with  key
informant  interviews  within  each  region.  An important  theme  is  the  increasing  role  of  individual
patients,  organisations  and  physicians  in  advocating  for  greater access  to and  fairer  prices  for  cancer
therapies.  Whilst  health  technology  assessments  (HTAs)  are  increasingly  prevalent  their  role in inform-
ing  reimbursement  policy  is  inﬂuenced  by public  and  political  scrutiny,  which  impacts  their  ability
to  ensure  access  to high  value  cost  effective  care. Austerity  measures  following  the  global  recession
have  created  inequities  in  access  to  drugs  with  concern  about  the  impact  on  subsequent  outcomes.  The
cancer  economics  debate  has  largely  centred  on  the  provision  of  drugs,  with  access  to  radiotherapy  and
over-penetration  of  high  cost  radiation  technologies  under-represented  in  media  outputs  and  political
discussion.
Future  work  should  enhance  collaborative  efforts  to assess  relative  effectiveness  and to  provide  real-
world  data.  These  debates  are becoming  increasingly  complex,  even  as we  face stagnating  health  budgets.
We  must  also  be aware  of the key  factors  that  play  a signiﬁcant  role  in  cancer  policy  aside  from  economics
including  socio-cultural  values,  advocacy  and  political  inﬂuence  at the  country  and  regional  level.© 2014  The  Authors.  Published  by  Elsevier  Ltd. 
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he case of Europe
ackground
With  respect to cancer care the US is estimated to spend approx-
mately 100D more per citizen compared to Europe as a whole
here it is estimated that per person cancer expenditure is 196D
1]. However there remains signiﬁcant debate as to whether this
as translated into improved patient outcomes [2,3]. Furthermore
everal EU-28 countries, despite less investment, are achieving
omparable or superior outcomes by considering best practices,
nd assessing cost effectiveness [4].
However, within EU-28 countries the landscape is heteroge-
eous, with on-going debate as to the optimum strategy to achieve
alue in the provision of cancer care [5]. The report by the Lancet
ncology Commission on the affordability of cancer in high-income
ountries has conceptualised the debate and we have set out in this
ection to review the changes and ethos of EU-28 countries towards
ancer economics [6].
readth  of the problem and the range of expenditures
Across Europe there remain signiﬁcant inequities in the inci-
ence of speciﬁc tumour types and outcomes of care. The overall
isk of dying is decreasing, in line with improvements in screening,
iagnosis and treatment, however variation in the magnitude of
hange exists according to disease site and country [7]. The CON-
ORD study demonstrated that ﬁve-year relative survival for breast
ancer in Europe ranged from 57.9% and 62.9% in Slovakia and
oland respectively to 75.5%, 79.8%, and 82% in Germany, France,
nd Sweden with regional variation evident [8]. Such trends have
een established in other studies, notably the Eurocare 5 report
nd The International Cancer Benchmarking Partnership Study [9].
actors implicated include late diagnosis associated with advanced
tage at presentation [10].
These ﬁndings were widely reported in the media [11] and stim-
lated public debate and political action with the creation of new
olicies designed to ameliorate regional and international dispar-
ties. Early diagnosis was considered a key policy goal to improve
ancer survival in the UK. Prevention, increasing awareness of can-
er symptoms and dissemination of best practice were all identiﬁed
s key goals in the government’s white paper “Improving outcomes
 strategy for cancer” [12]. Comparative data from observational
tudies on cancer outcomes has the ability to inﬂuence the debate
nd result in positive policy changes.
Although absolute cancer expenditures alone are not indicative
f outcomes, signiﬁcant differences are likely to reﬂect potential
ssues in access to essential screening, diagnostic and treatment
ervices as well as the political priority afforded to cancer care. A
ecent study [1] demonstrated that per capita cancer care expendi-
ure varies considerably across the EU, even for countries with the
ame level of national income. The UK, Italy, Sweden and France
hen adjusting for price differentials spend 92D, 96D, 92D and 97D,
espectively, per person on cancer speciﬁc health care. By compar- .  . .  . . .  .  . . .  . . .  . . . . . . .  . . . . .  . . .  . .  . . . . . .  . .  .  . . .  .  . . .  . . .  .  . .  .  .  . .  .  .  . . . . . .  . .  .  . . .  .  .  .  .  10
ison  Germany spends 171D per person and The Netherlands 123D.
However across Eastern Europe the differences are marked, with
adjusted costs per person per annum for Bulgaria, Romania and
Poland of 52D, 54D and 78D, respectively.
The effects of variation in expenditure and the comparative
effectiveness of health care interventions across Europe remain
difﬁcult to discern due to inconsistent poor quality data, and chal-
lenges of adjusting for case mix  when interpreting observational
studies[13]. Additionally factors other than wealth are important,
and unwarranted variation can result from limitations in health
insurance coverage, disparities in access, (e.g. radiotherapy), as well
as differences in country-speciﬁc cancer epidemiology [14–17].
The  global recession: end of an era in cancer investment?
A major factor inﬂuencing the current cancer economics debate
has been the austerity measures rolled out across Europe in
the face of the recession. Greece cut its health budget by 23.7%
between 2009 and 2011, Spain by 14% in 2012 and Portugal cut its
health spending for the ﬁrst time in 2011 [18]. In the UK, additional
pressure on NHS (National Health Service) budgets has been placed
by the “Nicholson challenge” which is seeking efﬁciency savings of
more than 20£  billion by 2015 in order to meet projected patient
demand [19]. In Italy, poor control of regional health care expend-
itures had resulted in a cumulative deﬁcit of over 38D billion [20].
Countries have attempted to reduce expenditures by encour-
aging efﬁciency savings through the use of generic drugs. Spain
has gone further with cuts to professional training (75%) as well
as public health and quality programmes (45%). There have been
cost shifts from the state to patients; with previously exempt
groups (e.g. pensioners) now required to make co-payments [21].
Rationing of health services have led to lengthening of waiting lists
for hospital procedures and tests and reduced availability of cancer
drugs across several countries in Europe.
In Romania there has been a chronic shortage of basic cancer
drugs over the last 2 years. Whilst under-investment in pharma-
ceuticals is a factor, it is the complex and fragmented procurement
and distribution pathway for drugs that has resulted in inconsistent
supply stimulating the black market and Internet sales. Further-
more, the costs of drugs in Romania are the lowest in the EU,
resulting in parallel exports whereby drugs are sold to other Euro-
pean states where the same drugs are usually more expensive [22].
Drug companies have reacted by tightening their conditions
for trading with European countries such as Greece [23,24]. How-
ever the overriding concern is the impact that inequities in drug
availability could have on cancer outcomes particularly for those
unable to pay privately. Exacerbating the situation is the fact that
the costs of cancer care in EU-28 countries are increasing at an
unprecedented rate, driven by demographic changes, innovation
and consumerism within health care [6]. Fiscal sustainability of
health care ﬁnancing therefore remains a key public policy concern.
Calls have been made to the European Commission to intervene on
this issue given concerns regarding patient welfare.
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The forum for the discussion has been the European Partner-
hip for Action Against Cancer (EPAAC) [25]. EPAAC was  set up
y the European Commission in 2009 to engage relevant stakehol-
ers across the EU to deal with the challenges European countries
ace in delivering cancer care. It encourages research collaboration,
issemination of evidence-based practice, measurement of out-
omes of care and the creation legislation that promotes healthier
ifestyles (e.g. anti smoking policies).
arriers to drugs access – the role of HTAs
In Europe price-setting and reimbursement decisions are
evolved to individual countries with EPAAC advocating the
ncreasing role of Health Technology Agencies (HTAs) in this pro-
ess [26].
However a review of market access of cancer drugs in Europe
hows inconsistency in the mechanism of reimbursement, the
se of cost effectiveness analysis in decision-making, and extent
f pharmaceutical price regulation schemes [27]. This had led to
nequities in drug access even amongst countries with similar lev-
ls of national income, although not necessarily causing differences
n patient outcomes. A UK Department of Health report assessing
he extent of international variation in drug usage in 14 countries
ound that Germany, France and the US were amongst the countries
ith the highest access, compared to the UK, Canada and Australia
hat had amongst the lowest [28].
In this regard, a poll of key stakeholders in the affordability
ebate at The Oncopolicy forum during the 2011 European Can-
er Organisation (ECCO) conference is indicative of current political
nd public debate on the issue. Participants cited the following as
auses of inequities in drug access across Europe: national funding
nd willingness to pay (42.2%), drug affordability (40.2%), clinicians’
on-adherence to guidelines (11.8%), health technology assess-
ent process (3.9%), and marketing authorisation (2%) [29].
Cancer  drugs represent a rising proportion of the cancer care
udget [30]. Governments have attempted to utilise HTAs to ensure
ational and fair decisions are made regarding resource allocation,
owever, attempts to control the provision of drugs not deemed
ost effective by HTAs such as NICE have met  widespread public
nd professional discontent [31,32]. These difﬁculties are exacer-
ated when the same drugs that have been refused in the UK are
idely available in the US and Europe. Between 2004 and 2008,
6 anticancer drugs were granted a European license following
DA approval. NICE made recommendations for 18 (39%) of these
rugs to be freely available on the NHS with 11 (24%) still awaiting
pproval. In contrast all of these drugs were covered by the three
ain insurance providers in the US [33,34].
Another major concern is the time taken to review new can-
er drugs. Relative to the FDA, the European Medicines Agency
ook longer and approved fewer drugs between 2003 and 2010
35]. It is not surprising that anticancer drug coverage decisions
hat also consider cost effectiveness are associated with great
estrictions and slower time to coverage. However despite these
rawbacks, such rigorous evaluation ensures that co-payments are
ot required at the point of access for drugs granted approval,
nhancing equity [34].
eterogeneity  in reimbursement mechanisms across EU-28
In  Sweden, value based pricing has meant that no cost effective-
ess thresholds are deﬁned, instead applying a societal perspective
o consider costs and beneﬁts of healthcare [36]. Likewise in
he Netherlands cost effectiveness thresholds are higher than for
ountries such as the UK (20–80,000£/QALY gained) and based on
isease severity and medical need, meaning high cost drugs are
ften approved [36]. Provisional reimbursement for four years canncer Policy 2 (2014) 1–11 3
be arranged for drugs which have insufﬁcient data to enable for-
mal  cost effectiveness evaluations or where uncertainty remains
[37].
Most countries have some form of risk sharing agreement for
high value drugs, be it ﬁnancial based agreements where rebates
are offered to third party payers for the cost of increased expendi-
ture over an annual subsidisation cap, or performance or outcome
based agreements [37]. In Italy, innovative new cancer drugs are
classiﬁed as Class H stipulating their use in the hospital setting.
Class H drugs are bought directly by hospitals from the manufactur-
ers, enabling them to beneﬁt directly from cost sharing agreements
and minimum discounts of 50%. These have enabled expansion of
patient access to pharmaceuticals [38]. Given national drug budgets
are ﬁxed, the utility of local or regional level HTA’s are diminished
[39].
France has the highest expenditure for cancer therapeutics
in Europe however there is a reluctance to encourage explicit
rationing despite the presence of a HTA body, to avoid denial of
potentially life-saving drugs [40]. Disease severity and drug efﬁcacy
are the main criteria rather than cost effectiveness and there-
fore high price innovative cancer drugs with signiﬁcant budget
impact are still likely to be reimbursed [41]. However legislation
introduced in 2012 is attempting to deﬁne indications for health-
economic evaluation for those drugs with signiﬁcant budget impact
[42].
Eastern European countries are attempting to formalise the role
of HTAs within strategic health decision making as noted by their
involvement in international collaborative efforts. However some
member states do not have the capacity or expertise to form an HTA
agency namely, Slovenia, Slovakia, Estonia, Malta and Luxembourg
[43].
The debate continually played out in the media is one of concern
about access to drugs and the potential effect on outcomes. Pub-
lic and political pressure has resulted in policy changes devised to
increase access albeit at signiﬁcant cost (Box1). A recent review
estimated that between 2009 and 2011 the additional cost to the
NHS of providing new interventions under the updated end of life
criteria was  549£ million per annum [44]. The Cancer Drugs Fund
has also required signiﬁcant ﬁnancial commitment with close to
1£ billion having been invested in the initiative. Deﬁnitive evi-
dence on its role in improving patient outcomes is awaited but
approximately 34,000 patients have gained access to high cost
drugs through the scheme [45].
Formal collaboration across Europe
Greater emphasis needs to be placed on ensuring ﬁscal sus-
tainability and the generation of policy ideas that will sustain
spending proportional to the projected rise in number of can-
cer cases, whilst embracing technological innovations that could
potentially improve outcomes. Formal collaborations have com-
menced across Europe to reduce this perceived disparity between
nations and to develop synergies that can beneﬁt what is politically
sensitive decision making. Consideration needs to be given for more
direct engagement of patients and public when setting the policy
agenda so that they are aware of the trade-offs (e.g. lengthening
waiting lists, co-payments) that may  result should access become
the sole priority [46].
Since  2006 the European Network for Health Technology Assess-
ment (EUnetHTA) has brought together established regional and
national HTAs across Europe as well as research groups performing
HTA activities in countries with no formal national HTA agency [47].
The European commission supports this collaboration. All mem-
bers of the European Union are represented with the exception of
Bulgaria and Slovakia.
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Box 1: Advocacy.
In  numerous instances individual patients, organisations and
physicians  have garnered attention advocating for greater
access  to and fairer prices for cancer drugs. In the UK, there
have  been a series of challenges over the last 10 years to deci-
sions  by NICE. Legal challenges resulted in the approval of both
trastuzumab  and imatinib despite the fact both exceeded the
30,000£ QALY threshold.1 These decisions were made against
a  background of legal action by patients, with its attendant
publicity, and some political pressure. Following approval of
sunitinib, NICE reviewed its policy for end of life drugs, specif-
ically  the value placed on gains in survival and quality of
life  for incurable conditions where there remains a paucity
of  reasonable alternatives.2 The U.K. Government has also
attempted  to further improve access by initiating the Cancer
Drugs  Fund, which was  ofﬁcially due to ﬁnish in January 2014
and  be replaced by value based pricing (VBP). However a fur-
ther  400£ million investment has extended its role until March
2016.3 These changes are examples of the key role played by
the  public and importantly the media in the cancer economics
debate.
However it is not necessarily a fair assumption that the pub-
lic  think coverage of new technologies irrespective of cost
is  appropriate. In a recent survey of societal preferences for
NHS  funding, respondents agreed with the premise of VBP,
but  the majority did not believe that extra value should be
placed  for speciﬁc groups such as children, cancer patients or
those  with reduced life expectancy.4 Another study reported
that  the majority of cancer patients and the general public did
not  believe the NHS should fund drugs that have not been
approved by NICE.5
In Canada a growing number of high-proﬁle cases of media
and  political inﬂuence have impacted drug approvals. A
salient  example is that of the 35-year old Ontario woman
whose breast cancer was HER2-positive, but less than 1 cm
in  size without evidence of lymph node involvement. Accord-
ing  to Cancer Care Ontario evidence based guidelines in
2011  she would not qualify for public funding of trastuzumab
(Herceptin®). Citing the inter-provincial inequities to access,
a  massive letter-writing campaign to the Ontario Ministry of
Health  coordinated by patient advocacy groups6 led the provin-
cial  “public watchdog”, Ombudsman Ontario, to launch an
investigation.7 Heavy media coverage ensued8 and within
weeks  the Ministry announced that it would fund trastuzumab
for  tumours less than 1 cm through Cancer Care Ontario’s new
Evidence-Building Program.9 Ombudsman Ontario dropped
their  investigation.10
While in the US, physician advocacy may  be increasing. Recent
examples  of vocal advocacy include: (1) the opinion piece co-
authored  by three Memorial Sloan Kettering (MSK) physicians
in  the New York Times that decried the planned charge for aﬁl-
bercept  (Zaltrap®), a “VEGF-trap”, that is neither better nor less
toxic  than bevacizumab but was to cost twice as much11; and
(2)  an editorial signed by 119 chronic myeloid leukaemia (CML)
experts  that addressed “the multiple factors involved in cancer
drug  pricing and their impact on individual patients and health
care  policies”, and argued “for the need to (1) lower the prices
of  cancer drugs to allow more patients to afford them and (2)
maintain  sound long-term health care policies”.12 In the case of
aﬁlbercept  the company “reduced” prices by more than 50%,
earning  the MSK  physicians praise from the New York Times13;
while in the CML  advocacy the outcome remains to be seen.
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Since 2010 the EUnetHTa has been collaborating with the EMA
following a direct mandate from the Pharmaceutical forum with
the aim of improving the availability and best use of data rele-
vant to Health Technology Assessment [48]. In November 2013 this
collaboration announced a three-year work plan. Key areas include:
(1) Developing approaches for collection of post-authorisation
data to support activities of regulatory agencies and HTAs.
(2) Facilitate clinical trial design to enable generation of data
relevant  for both beneﬁt-risk and relative effectiveness assess-
ments.
(3) Orphan medicinal products – exploring ways of sharing infor-
mation  for the common beneﬁt of patients with rare diseases
whilst  ensuring ﬁnancial sustainability.
Where do radiation therapies stand in the cancer economics
debate?
The  debate on cancer economics has largely focused on expen-
sive cancer drugs. However a less mature debate amongst EU-28
countries concerns the evaluation of radiation technologies, an
area that has undergone signiﬁcant development over the last
5–10 years. Radiotherapy is considered a necessary component of
treatment in 52% of all newly diagnosed cancers [49]. Taking into
account all costs across the life cycle of the resource, it is, broadly
speaking more cost effective than surgery and chemotherapy [50].
However, the UK as with other European countries is in a paradox-
ical situation where delivering affordable radiotherapy over the
next twenty years is being compromised by both current under-
capacity and underinvestment in ‘standard’ radiotherapy and also
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ver-penetration of newer radiotherapy technologies that have far
reater associated costs [51].
A recent analysis of Directory of Radiotherapy Centres (DIRAC)
atabase demonstrated variation in radiotherapy capacity and
uality across the EU[52]. The average number of megavoltage
eletherapy machines per million of the population varies from
.3, 2.8, 2.0 in Romania, Poland and Bulgaria respectively com-
ared to 6.5, 7.6, 8.2 and 9.7 in France, The Netherlands, Sweden
nd Denmark respectively. In the former group of countries there
s signiﬁcant unmet radiotherapy need with a requirement to mod-
rnise capital infrastructure. The UK has 5.4 machines per million
f the population however it is estimated that for the UK to meet
rojected demand by 2016, will require a 67% increase in current
apacity requiring an extra 147 radiotherapy machines [53].
The  quest to improve the therapeutic ratio (i.e. maximise
umour dose while limiting dose to normal tissues) has resulted
n the development of innovative radiation technologies such as
ntensity modulated radiotherapy (IMRT), stereotactic radiothe-
apy and particle therapy e.g. proton therapy [54–56]. Whilst they
ffer the potential to reduce long term toxicity through improve-
ent in dose deposition and accurate target localisation, there
emains a paucity of randomised evidence of their beneﬁt in achiev-
ng clinically relevant improved outcomes [49,57,58]. To inform
he discussion, ESTRO (European Society for Radiotherapy and
ncology) has launched the HERO (Health Economics in Radiation
ncology) project to develop a knowledge base and a model for
ealth economic evaluation of radiation treatments at the European
evel [59].
Of  all the new technologies, the case of radiotherapy demon-
trates the paradox of public policy towards affordable cancer care.
 failure to deliver basic service needs, yet willingness to ‘over-
pend’ on technologies that have not been demonstrated to be
ost effective. However stimulating debate in this area remains
 challenge, as it appears the public identify more with concerns
egarding drug access than radiotherapy. This despite evidence that
he estimated impact of chemotherapy on 5-year survival for all
ancers is 2% compared to 16% overall for radiotherapy [60,61].
he role of the pharmaceutical industry in driving the debate needs
o be considered when reviewing this paradox, with pharmaceu-
ical companies known to support patient lobbying groups when
unding decisions of new technologies are being considered [62].
ancer  economics debate – the case of Canada
verview – the Canadian system
As in the US and EU drug costs are rising and in Canada are the
econd largest health care expense (public and private) after hospi-
als [63]. Total health expenditure in Canada was $CAD 200.1 billion
n 2012. Per capita health expenditure was $CAD 5803 in 2011, and
s forecast to reach $CAD 5988 for 2013 [63]. The Canadian Cancer
ociety estimated that in 2013, 187,600 Canadians would be diag-
osed with cancer and 75,500 would die of cancer. Approximately
 in 5 Canadians will develop cancer and 1 in 4 will die of their
isease [64]. Fifty-two percent of new cases will be lung, breast,
olorectal and prostate cancer.
A recent analysis of all healthcare costs for the province of
ntario estimated a mean of $CAD 27,560 per patient in the year
fter diagnosis [65]. This included direct health care costs such as
npatient and outpatient care, intravenous chemotherapy, outpa-
ient drugs, radiotherapy, same-day surgery and diagnostic tests.
hey did not estimate indirect costs, lost productivity or other
xpenditures. Costs varied considerably according to tumour site
nd 1-year survival. There was also variation according to geo-
raphical location with more remote areas of the province incurringncer Policy 2 (2014) 1–11 5
higher  costs, which the study authors suggest may  be due to a later
stage at diagnosis. There is little reliable national data on direct or
total health care expenditures for cancer. However, based on the
Ontario data and assuming similar disease burden and costs in all
Provinces, the same report estimated healthcare costs from the ﬁrst
year of diagnosis to be as high as $CAD 484 million for colorectal
cancer, $CAD 453 million for lung cancer, $CAD $267 million for
breast cancer and $CAD 238 million for prostate cancer. Using 2009
GDP of $CAD 1.5 trillion, the ﬁrst-year costs for colorectal, breast,
lung and prostate cancer combined would represent approximately
0.09% of Canada’s GDP [65].
While cancer survival in Canada compares favourably with the
US and the EU [8,11] new drug approvals by Health Canada remain
slow [66,67], and the absence of a common pharmaceutical pol-
icy creates some inequities in access and pricing across the ten
provinces. Canada’s publicly funded health care system is based on
the principle of universal coverage for “medically necessary health
care services provided on basis of need, rather than the ability to
pay” [68]. While public coverage for physician and hospital ser-
vices is 100%, there is no legislated national coverage for drugs or
home and community care services, with the exception of drugs
administered in hospital. Provinces hold jurisdiction for decision-
making regarding public funding of and pricing for new medicines
including cancer drugs [68,69].
The national health system, known as “medicare”, can be best
described as an “interlocking set of ten provincial and three terri-
torial health insurance plans” [68]. However, unlike many other
unitary states, Canada as a federation does not have a national
health insurance plan but has 6 federal, 10 provincial and 3 ter-
ritorial tax-payer funded plans in addition to thousands of private
insurance plans. Health Canada, the government Ministry charged
with setting and administering the principles of the Canada Health
Act, assists in the ﬁnancing of provincial/territorial health care ser-
vices through ﬁscal transfers, in the form of cash or tax points,
conditional on meeting the principles of the Act [70]. Tax points
transfers occur when the federal government reduces some of its
taxes enabling provinces to raise theirs by the same amount. The
result is an increase in provincial revenues, with no increase in
the total tax burden borne by Canadians. In effect the federal gov-
ernment steers policy through the indirect means of its spending
power.
While Health Canada delivers health care services to speciﬁc
groups including the aboriginal groups, First Nations and Inuit,
for the vast majority of Canadians, provinces are responsible for
the organisation, ﬁnancing and delivery of health services includ-
ing approvals and pricing for new drugs and technologies. Any
drug approved by Health Canada can theoretically be paid for out
of pocket, however many intravenous and oral cancer drugs are
publicly funded, albeit with considerable variation across juris-
dictions [71]. Those not publicly funded may  be covered through
private insurance/third party coverage (about 60% of Canadians), or
through special provincial coverage for the elderly or those on social
assistance [72]. Individuals may  purchase some intravenous cancer
drugs not publicly funded. In some provinces including Ontario,
a few private chemotherapy infusion clinics were established in
the mid 2000s [73]. Debate is on-going regarding the utilisation
of public health infrastructure (i.e. pharmacy, nursing, and space
resources) for patients who  choose to pay for unfunded drugs; both
Ontario and the UK have adopted a more permissive approach to
this matter [74].
Canada  – challenges and solutionsIn 2005 Ontario published the ﬁrst 3-year provincial cancer
plan that included several hundred million dollars in capital and
health services investment. The province also began to (1) report
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ystematically on system performance through the Cancer Sys-
em Quality Index (CSQI [75]); (2) include indicators and targets
cross the cancer control continuum; (3) support a strategy for
mproved national surveillance, performance and risk assessment;
nd (4) identify areas of strategic priority for investment [75].
he Ontario-based Committee to Evaluate Drugs (CED) is the Min-
stry’s independent expert advisory committee on drug-related
ssues. The CED evaluates the clinical value of drug products, inter-
hangeability of generic drug products and cost-effectiveness of
rugs through evidence-based reviews. These reviews result in rec-
mmendations being made to the Executive Ofﬁcer regarding the
overage of these products through the Ontario Public Drug Pro-
rammes and ultimately the Executive Ofﬁcer at the provincial
inistry of Health, makes ﬁnal decisions whether or not to list a
ew drug in the public system and at what price.
Meanwhile, at the national level, in 2006 the Canadian Strat-
gy for Cancer Control published the ﬁrst national cancer plan [76].
o implement the new strategy the Canadian Partnership Against
ancer (CPAC), an independent non-proﬁt organisation with fed-
ral government funding was launched, with $CAD 250 million
ver 5 years; this has since been renewed. In March 2007 the inter-
rovincial Joint Oncology Drug Review (JODR) was developed and
n 2010 became the Pan-Canadian Oncology Drug Review (pCODR),
ith a broader nationwide representation. pCODR provides clinical
nd pharmacoeconomic assessment of new drugs, at the request of
rovincial cancer agencies, pharmaceutical companies or other rel-
vant stakeholders. With the exception of the initial price offered by
harmaceutical companies, pCODR processes are transparent and
ll reviews including details of deliberations and input from patient
dvocacy groups are publicly available online [77]. The pCODR pub-
ishes their ﬁnal recommendations, which are then considered by
ndividual provincial formulary mechanisms. In November 2013
n online lay-oriented tutorial was posted, to inform health pro-
essionals and the public on how cancer drug funding decisions are
ade [78].
To  date the majority of pCODRs recommendations have been
pprovals, but these are almost always “conditional on the
ost-effectiveness being improved to an acceptable level” (e.g.
pilimumab for stage II/IV melanoma [79]). Despite mechanisms
o ensure timely, equitable recommendations based on clinical
vidence and cost-effectiveness, the adoption of pCODR recom-
endations is uneven across the country. Some provinces may
ecide against listing a new cancer drug for a variety of reasons,
he most salient of which is the absence of conventional cost-
ffectiveness [74]). Despite the lack of national coverage standard
or drugs, over a 2–3 year period following submission for con-
ideration of a drug for funding, there does appear to be ‘soft’
armonization of the formularies, as provinces tend to adopt com-
on  cancer drug coverage over time.
How each province sets the ﬁnal price is coming under greater
crutiny with efforts underway to reduce inter-provincial differ-
nces. First, the Patented Medicine Price Review Board (PMPRB)
ets a “ceiling price” nationally and this effectively becomes a ﬂoor
rice for a pharmaceutical company. PMPRB is an independent,
uasi-judicial body established by Parliament in 1987 [80] Accord-
ng to the PMPRB mandate a new brand-name drug in Canada
an never be the most expensive in the world, and drugs already
pproved cannot increase by more than the Consumer Price Index.
he cost of a new drug is considered as excessive if it exceeds the
ighest price of the same strength and dosage form of the same
atented drug product for each country listed in the Regulations
France, Germany, Italy, Sweden, Switzerland, the United Kingdom,
nd the United States) [81]. Upon considering pCODR’s recommen-
ation to list a new drug, it is then within each provincial Ministry
f Health that closed door deliberations take place, leading to a ﬁnal
rice being offered to the pharmaceutical company. In some cases,ncer Policy 2 (2014) 1–11
such  as erbitux (Cetuximab®) in Ontario, a pharmaceutical com-
pany may  choose to withdraw their request for approval on the
basis of this ﬁnal price, leaving patients to seek funding through
private insurance. This process too will soon be more transpar-
ent, and harmonized across the country via a new mechanism, the
Pan-Canadian Pricing Alliance. The goals of the alliance are to: (1)
increase access to drug treatment options; (2) improve the con-
sistency of drug listing decisions across the country; (3) capitalise
on combined buying power of jurisdictions; (4) achieve consis-
tent pricing and lower drug costs; and (5) reduce duplication of
negotiations and improve utilisation of services [82].
Cancer economics debate – the case of the United States
Finally,  we  examine the US system, exploring the efﬁcacy of
cancer therapeutics and the value and limitations of clinical trial
results, important factors that should inform and inﬂuence health
policy decisions.
The  US healthcare system – attributes, deﬁciencies and on-going
changes
The  system for approving cancer therapeutics in the US is rel-
atively straightforward. After initial consultations with the United
States Food and Drug Administration (US FDA) the sponsor sets
out to achieve previously agreed to endpoint(s). Approval will
likely be granted if results are statistically valid and the drug gen-
erally tolerable. Importantly the US FDA does not discriminate
against therapies similar to already approved therapies, as dis-
cussed below. Following US FDA approval the Centres for Medicare
and Medicaid Services (CMS) grants its approval as do a major-
ity of insurance companies often looking for guidance from groups
such as the American Society of Clinical Oncology (ASCO) and the
National Comprehensive Cancer Network (NCCN). Unlike Europe
where European Medicines Agency (EMA) approval requires sub-
sequent approval by nations, US FDA approval covers all ﬁfty states
and the District of Columbia. Also because the US FDA  does not
consider costs and CMS  is forbidden from negotiating prices, cost
is not a factor neither in approval nor deployment of therapeu-
tics. The law forbidding CMS  from negotiating prices is a subject
of debate. As in the EU and Canada, the US system is subject
to both societal and political pressures. Nearly everyone agrees
with this, although not everyone agrees whether this is harmful or
beneﬁcial.
The current health care burden and where it may  go
A  recent Council of Economic Advisers report noted that medical
spending is slowing [83]. Per-capita health-care spending rose just
1.8 percent annually from 2007 to 2010 and even slower since then.
While some of the slowdown can be explained by the recession and
the slow recovery, many believe other factors may  also be at work.
As to the future, “structural changes” such as insurance plans with
narrower networks of hospitals/doctors and changes in incentives
may begin to have a salutary effect. Additionally, higher deductibles
and co-pays will likely bring value into focus. In cancer, efﬁcacy and
novelty of therapies are likely to emerge as even more important
factors.
Cancer therapeutics: are we getting what we pay for?While much has been written about the cost of cancer thera-
peutics, the problem is not that therapies are expensive, but that
for the beneﬁt they deliver, their costs are excessive [84–87]. Look-
ing at cancer therapies approved by the US FDA for solid tumours
l of Ca
b
ﬁ
2
t
i
h
r
I
t
c
T
e
i
a
i
b
r
p
2
c
t
l
t
a
m
i
i
S
r
i
i
n
t
F
p
“
yA. Aggarwal et al. / Journa
etween 2002 and 2012, one ﬁnds surprisingly small median bene-
ts with progression-free and overall survivals prolonged 2.15 and
.16 months, respectively [88]. Even more important: (1) combina-
ion therapies have repeatedly failed (inhibitors of BRAF and MEK
n melanoma as exception [89,90]); and (2) their use sequentially
as proven disappointing. Consider examples in metastatic colo-
ectal cancer (mCRC) and metastatic renal cell carcinoma (mRCC).
n mCRC, gains have stagnated. The recently published ML18147
rail, a prospective study in which bevacizumab was given with all
hemotherapy regimens achieved a survival of 23.9 months [91].
his was disappointingly indistinguishable from survival a decade
arlier in a GERCOR study without bevacizumab that reported sim-
lar survivals of 21.5 and 20.6 months [92]. While in mRCC one ﬁnds
 similar stagnation in beneﬁts even as the number of options has
ncreased. To be sure, gains have been made. In the population-
ased Surveillance, Epidemiology, and End Results (SEER) cancer
egistry survival between 2000 and 2003 before “targeted thera-
ies” was 15 months compared to 20 months between 2005 and
008 in the “targeted therapy” era [93]. But the evidence also indi-
ates beneﬁts may  have reached a plateau. In a recently published
rial the estimated survival of 29.3 months with sunitinib [94] over-
apped the value of 26.4 months achieved with sunitinib in a trial
hat enrolled patients ﬁve years earlier [95].
Can this be true? Has improvement in overall survival in mCRC
nd mRCC reached plateaus? The SEER data shows gains in the com-
unity are much less than in clinical trials – survivals of 20 months
n the era of targeted therapies, compared with 26.4–29.3 months
n clinical trials bracketing this period [93–95]. Furthermore, the
EER data shows new therapies have had limited impact on both
enal cell and colorectal cancer survival (Fig. 1). How can it be that
n mRCC despite approval of seven drugs since 2005, improvement
n survival rates has been disappointing? Amongst several expla-
ations, the class of the drugs approved and the design of clinical
rials stand out.
ig. 1. Survival rates for renal cell and colorectal cancers in the era of targeted therapie
elvis cancer rose on average 1.7% each year from 2000 to 2010 with death rates falling o
targeted therapies” and could be explained by earlier detection and better surgical inter
ear  during this period, coincident with a 2.9% fall in the rates of new colon and rectum cncer Policy 2 (2014) 1–11 7
The impact of drug class underscores an attribute of the US FDA
that is also a drawback – it largely ignores the class of the drug under
review. Nearly identical drugs can seek approval for similar indica-
tions; and provided efﬁcacy and safety are demonstrated, approval
is likely. The FDA believes it is not in their purview to decide if a
similar drug is or is not needed – marketplace forces will decide.
Thus, four of seven drugs approved for renal cell carcinoma inhibit
the vascular endothelial growth factor receptor (VEGFR) [96] and a
ﬁfth targets the ligand (VEGF) [97]. While the other two are deriva-
tives of sirolimus [98]. Having very similar options has added little
to survival. Patients are not living substantially longer, and receive
drugs sequentially at no greater cost.
What about the design of clinical trials? Unfortunately they
do not represent the general population. The importance of this
is underscored by a report from the International Metastatic RCC
Database Consortium study [99]. Trial eligible patients survived
28.4 months, but the 35% of patients that did not satisfy standard
trial eligibility criteria had a discouraging 12.5 months survival. The
authors concluded, “The number of patients ineligible for clinical
trials is substantial and their outcomes are inferior. Speciﬁc tri-
als addressing the unmet needs of protocol ineligible patients are
warranted.”
Patients enrolled in clinical trials are “better ﬁt” and younger
[100] underscoring the ﬂaw in extrapolating clinical trial results to
all patients, especially in policy decisions. The US SEER data cited
above [93], for example, found age older than 65 a predictor of a
shorter survival. And in the ﬁfty-seven trials supporting the forty-
eight FDA approvals between 2002 and 2012, enrolled patients
were generally younger than those in the community with the same
cancer and in the majority older patients achieved less beneﬁt [88].
An additional consequence of this disparity is poorer tolerability in
the community as seen in an observational study of patients with
hepatocellular carcinoma treated with sorafenib in which the rates
of dose reduction and discontinuation were 50–100% higher in the
s. Using statistical models, the SEER data ﬁnds the rates for new kidney and renal
n average 0.6% each year over the same period – a trend that antedates the start of
ventions. While for colorectal cancer death rates have fallen on average 2.8% each
ancer cases.
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bservational study [101] than in the original report [102]. The
lderly can also be expected to gain less from ensuing therapies.
These  facts are important for society and pharmaceutical com-
anies. In mRCC, for example, initial surgical costs are “built into
he system” so that going forward the administration of expen-
ive therapies to patients with metastatic disease will drive higher
osts. Unfortunately, as discussed, the length of that time has not
ncreased appreciably despite seven new therapies and outlays by
ndividuals and society will not change much in the near term –
ndeed as drug patents expire, costs may  decrease. Novel thera-
eutics may  yet add some beneﬁt and cost, but this will likely
e incremental. For society this offers the possibility the rate of
ncrease of oncology drug prices fro some cancers may  now fall. As
or pharmaceutical companies one would think the experience in
RCC with “me  too drugs” that do not substantially prolong sur-
ival when used sequentially but must compete for market share
ould be instructional. But unfortunately “me  too” drug devel-
pment is not likely not go away – inhibitors of the anaplastic
ymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) as
n example in a very small market. And although “me-too drugs”
ay be viewed as a safe investment, for society it is unacceptable
o have patients enrolled in clinical trials involving drugs that are
ither never approved or do not yield the needed gains in survival.
ancer patient outcomes in the United States
Finally we turn to allegations cancer patient outcomes in the US
re less than would be expected for its investment. Lets begin by
rst looking at some of the data within the United States that speaks
o these allegations, then consider very basic facts, and conclude by
assigning responsibility”.
Data  from the World Cancer Research Fund International [103]
hows the rate for all cancers (excluding non-melanoma skin can-
ers) was 1.73 times higher in more developed compared with less
eveloped countries (255.8 versus 147.8 per 100,000 population).
uch data imply greater wealth leads to greater cancer risk, but the
nited States data suggests a threshold exists, and that all Amer-
cans exceed this threshold (Fig. 2). Furthermore, wealth confers
nly limited advantages suggesting gains in cancer survival have a
hreshold above which additional expenditures bring diminishing
eturns (Fig. 3). Consistent with this, SEER-Medicare linked data
ound no consistent association between mean regional Medicare
pending and survival [104].
ig. 2. US data showing plots of cancer incidence across the ﬁfty states and the District
overty level. The data show that in the US cancer is not a disease of the wealthy, but a dis
ncidence Rates by State. 2010 data. All Cancer Sites Combined for both Males and Fema
opulation (19 age groups – Census P25-1130).ncer Policy 2 (2014) 1–11
Why  do greater US expenditures not bring better outcomes or
at least outcomes commensurate with outlays? Expensive thera-
peutics conferring modest or marginal beneﬁts is one explanation.
But pharmaceutical companies bristle at this focus, arguing this is
only a fraction of health care expenditures. Admittedly self-serving,
this argument has some validity since doctor’s fees, expensive
diagnostics, excessive procedures by innumerable consultants and
skyrocketing intensive care unit costs contribute enormously. And
more importantly, a large percentage of these outlays occur at what
many might consider inappropriate times. For example, the data
show a quarter of total cancer care expenditures occur in the last
year of life with a large portion in the last 30 days [105]. Given
healthier cancer patients derive the greatest beneﬁt from any inter-
vention much is being spent when the return on investment can be
expected to be very low, and current data is not encouraging for a
solution in the near term [106].
Consider recent data from the Dartmouth Atlas Project [105],
an endeavour that uses Medicare data to provide information
and analysis about hospitals and their afﬁliated physicians at a
local, regional and national level. Its 2010 report (Table 1) found
mixed results when looking at trends in end-of-life cancer care
across the country: (1) fewer days hospitalized but increased
number in intensive care in the last month of; (2) Increase in
hospice days but often beginning in the last three days of life; (3)
increase in percentage of patients who  saw ten or more physicians
during the last six months of their lives; (4) not much change in
endotracheal intubation, feeding tube placement, and cardiopul-
monary resuscitation during the last month of life or percentage
of patients receiving chemotherapy during the last two weeks
of life. The report concluded: “Despite the increased frequency of
end-of-life discussions, cancer treatment has become more aggressive
in general. It could be that some patients prefer more aggressive care,
or do not fully understand – or accept – that their life expectancy is
limited when expressing their preferences. Alternatively, end-of-life
discussions may occur too late in the course of illness to have a serious
impact on treatment . . . the ﬁndings . . . suggest that there is more
work to be done to ensure the wishes of cancer patients facing the end
of their lives are elicited, understood, and honored.”
Finally we turn to “assigning responsibility”, and in the US
system there is plenty of “responsibility” to assign. Consider the fol-
lowing: As a society the US expects results too often fuelled by hype
in the lay press. Patients and their families, read about the imminent
cure of cancer, the personalising of medicine and how cancer can
now be a chronic disease and feel hopeful [107–109]. They present
 of Columbia as a function of median income or percent of households below the
ease of Americans. Median income: In USD. Incidence: Age-Adjusted Invasive Cancer
les. Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard
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Fig. 3. US data showing plots of cancer death rates as a function of median income or percent of households below the poverty level. The data show that in the US greater
wealth confers only limited advantages. Although the correlations are statistically signiﬁcant, the data show that wealth (or percent of households below the poverty level
as  a surrogate) can only account for at most 17–22 to percent of the variance. The latter may  be explained if gains in cancer survival have a threshold above which additional
expenditures bring diminishing returns. Median Income: In USD. Rates Death: Age-Adjusted Cancer Death Rates by State. 2010 data. All Cancer Sites Combined for both Males
and  Females. Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25-1130).
Table 1
National trends in selected measures of the care of cancer patients near the end of life.
Measure 2003–2007 2010 Percent change, 2003–2007 to 2010
Number of deaths among cancer ill patientsa 235,821 212,322 −10.0%
Percent  of deaths occurring in hospital 28.8 24.7 −14.4%
Percent  hospitalized, last month of life 61.3 62.2 +1.5%
All  hospital days per patient, last month of life 5.1 4.8 −5.2%
Percent  admitted to ICU, last month of lifeb 23.7 28.8 +21.6%
ICU  days per patient, last month of lifeb 1.3 1.6 +21.2%
Percent  receiving life-sustaining treatment, last month of life 9.2 9.4 +3.1%
Percent  receiving chemotherapy, last two  weeks of life 6.0 6.0 +0.7%
Percent  enrolled in hospice, last month of life 54.6 61.3 +12.2%
Hospice  days per patient, last month of life 8.7 9.1 +4.3%
Percent enrolled in hospice within three days of deathc 8.3 10.9 +30.9%
Percent  seeing 10 or more physicians, last six months of lifed 46.2 58.5 +26.8%
Adapted from the Dartmouth Atlas of Health Care Brief [105].
a The estimate for 2003–2007 was created by summing a 20% sample over ﬁve individual years.
b Previous research has shown use of ICU resources is in part driven by the “supply”.
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mTime period too brief to provide patients full beneﬁt of hospice care.
d Although the Dartmouth Report authors interpreted this diversity of physicians
ossibility implicates an increase in the number of specialists recruited to consult o
o their oncologist expecting a cure or at a minimum a decade of life
 often with expensive, “personalised results” that have not been
alidated but that they think will ensure success [110,111]. Many
ptions will be “me-too drugs” one can argue should never have
een but were developed and are often very expensive – in part
ecause many other “me-too drugs” did not succeed adding cost to
ompany ledgers that must be “recovered”. Additional expenses
ere incurred because academicians with pharmaceutical com-
any support conducted large multi-institutional trials. These were
eeded because participation in clinical trials has reached intoler-
ble lows [112] and large numbers were needed quickly to achieve
tatistical signiﬁcance for the expected marginal beneﬁts before
he competition. Additional expenses occurred because the trials
ave become increasingly burdened by regulations, the majority of
hich, many have argued, have not made patients safer, but have
ade trials difﬁcult and expensive [85,113].
Unfortunately expensive therapies are not curative, too often
eliver only marginal beneﬁts, and in the majority the cancer
ecurs. Hard-working, dedicated oncologists wanting to help their
atients who wish to “continue ﬁghting”, all too often demure and
ontinue treating when they should not. They reach for unproven
rugs or combinations, many extraordinarily expensive, or for regi-
ens proven only in ﬁrst line but found in various guidelines as aggestion “more patients may  have experienced fragmented care”, an equally likely
g cancer patients for whom little that is meaningful can be done.
fourth line alternative where it provides little or more likely no
beneﬁt, but at great cost – ﬁnancially and in terms of toxicity. Or
the oncologist administers “off-label”, often at great expense to the
patient, a “novel therapy” that has never been proven beneﬁcial in
the setting being used. The oncologist knows nothing has worked
in the past and in desperation looks to something “novel”. But the
problem is not drugs from the past were ineffective; the problem is
the cancer is refractory and will not respond to this novel, expensive
therapy. The oncologist knows the remote chances of a meaningful
outcome; the patient encounters the certainty of ﬁnancial costs and
toxicities that impact the quality of their remaining lives. Only in
the end, when less than two weeks of life remain, does the “average
cancer patient” in the US seek out hospice.
Conclusion
Signiﬁcant heterogeneity exists in both expenditure and out-
comes of cancer care. The demographic transition means that
cancer remains at the forefront of the public and political con-
sciousness with numbers expected to rise as populations’ age.
Austerity following the global recession has brought its own unique
set of challenges with concerns regarding cuts to cancer spend-
ing to reduce public expenditure. HTAs have been initiated across
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uch of Europe and have started to collaborate in order to identify
igh value drugs which are likely to improve outcomes over and
bove those currently used, taking into account resources and dis-
ase characteristics within the population. However the degree of
ptake of these decisions and their impact on prescribing policy is
ariable, with challenges to several decisions resulting in a change
o reimbursement policy in countries such as the U.K.
A  less mature debate is the impact of new radiation technolo-
ies in driving the costs of cancer care. Due to methodological
imitations of conducting radiotherapy trials, evaluation of relative
ffectiveness remains limited however greater attention needs to
e given to rigorous evaluation of new technologies coming to mar-
et in the EU, as per pharmaceuticals. Imaging modalities similarly
equire tighter budgetary controls given their myriad of indications.
Throughout the world how to deal with the cost of cancer care
emains a work in progress. It is clear all countries are earnestly
rying to achieve equitable availability of therapeutic options, as
fﬁciently as possible, mindful of the increasingly limited resources.
uture work should enhance collaborative efforts on assessing rel-
tive effectiveness. Unfortunately this is as much a cultural and
olitical issue as one related to affordability.
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